Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dual Trigger With Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin to Optimize ICSI Reproductive Outcomes

Trial Profile

Dual Trigger With Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin to Optimize ICSI Reproductive Outcomes

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 03 Jun 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Triptorelin (Primary) ; Choriogonadotropin alfa
  • Indications Infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 25 May 2015 Status changed from discontinued to recruiting according to ClinicalTrials.gov record.
    • 25 May 2015 Protocol has been amended to increase treatment arms from 2 to 3 and planned number of patients from 400 to 800.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top